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Abstract
Purpose: Quantifying chromosomal instability (CIN) has both prognostic and predictive clinical utility in breast cancer. In
order to establish a robust and clinically applicable gene expression-based measure of CIN, we assessed the ability of four
qPCR quantified genes selected from the 70-gene Chromosomal Instability (CIN70) expression signature to stratify outcome
in patients with grade 2 breast cancer.
Methods: AURKA, FOXM1, TOP2A and TPX2 (CIN4), were selected from the CIN70 signature due to their high level of
correlation with histological grade and mean CIN70 signature expression in silico. We assessed the ability of CIN4 to stratify
outcome in an independent cohort of patients diagnosed between 1999 and 2002. 185 formalin-fixed, paraffin-embedded
(FFPE) samples were included in the qPCR measurement of CIN4 expression. In parallel, ploidy status of tumors was assessed
by flow cytometry. We investigated whether the categorical CIN4 score derived from the CIN4 signature was correlated with
recurrence-free survival (RFS) and ploidy status in this cohort.
Results: We observed a significant association of tumor proliferation, defined by Ki67 and mitotic index (MI), with both CIN4
expression and aneuploidy. The CIN4 score stratified grade 2 carcinomas into good and poor prognostic cohorts (mean RFS:
83.864.9 and 69.468.2 months, respectively, p=0.016) and its predictive power was confirmed by multivariate analysis
outperforming MI and Ki67 expression.
Conclusions: The first clinically applicable qPCR derived measure of tumor aneuploidy from FFPE tissue, stratifies grade 2
tumors into good and poor prognosis groups.
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Introduction
Chromosomal instability (CIN) is a key determinant of
biological behavior of breast cancer [1], yet remains challenging
to determine using high throughput methodologies [2]. We and
others have shown that CIN may play a role in determining
response to taxane treatment in ovarian cancer [3] and intrinsic
multidrug resistance in colon cancer [4] and it also appears to be
an important determinant of breast cancer prognosis [5,6]. While
direct determination of CIN by counting centromeres in a
sufficient number of breast cancer cells or measuring DNA index
is possible [7], it is technically challenging and time-consuming
[8,9]. Consequently, a simple measure of CIN, based on for
example qPCR measurement of a handful of genes, would greatly
facilitate its introduction into general oncological practice.
Therefore, we decided to investigate whether a clinically
implementable a qPCR-based gene expression based CIN
measure could be created. The ability of such signatures to reflect
CGH based genomic instability has been previously demonstrated
[5].
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is further emphasized by its complex relationship with histological
grade [10]. It has been known for many years that grade 2 tumors
classified by the Nottingham grading system display heterogeneous
characteristics in terms of clinical outcome [11,12]. It has also
been shown that relatively simple gene expression based methods
were able to stratify grade 2 cases into low risk and high risk
patients in a robust fashion [13]. Genes intimately involved with
CIN prominently featured in such gene expression signatures, but
it has become clear recently that quantifying ploidy has improved
prognostic potential than stratifying intermediate histological
grade in terms of clinical outcome. The vast majority of hormone
receptor negative cases (ER-/PgR-/HER2-) fall into histological
grade 3 category [14], but even within those, the level of CIN may
define subgroups of patients with distinct clinical outcomes [5].
Therefore in this study, we determined a minimal gene set that
seems to capture the information contained in the previously
published CIN70 signature, tested its correlation with directly
quantified CIN and verified its ability to stratify grade 2 breast
carcinomas according to good and poor clinical outcome in
routine formalin-fixed, paraffin-embedded (FFPE) pathological
samples. We compared the predictive power of the resulting
signature to mitotic index and Ki67 expression.
Materials and Methods
In silico selection of CIN genes for expression analysis
All microarray data sets used in this analysis were normalized by
robust multi-array average (RMA) [15]. Probe sets to represent
each gene in the various signatures (CIN70 [1], NKI70 [16], 21-
gene Recurrence Score (DX21) [17], intrinsic subtype [18],
Ivshina’s molecular grade [11], Ma’s 5-gene HOXB13:IL17BR
ratio (Ma5) [19], Sotiriou’s Genomic Grade Index (GGI) [20])
analyzed were selected by Jetset as described previously [21]. If no
reliable probe set was found for a given gene that was excluded
from further analysis. The data sets are displayed in Table S1.
Tissue samples
Focusing on histological grade, we evaluated 185 invasive breast
carcinomas consisting of 63 grade 1, 62 grade 2 and 60 grade 3
FFPE tissue samples regardless of other pathological features from
the Buda MA ´V Hospital (1999–2002), diagnosed and graded by a
single pathologist (J.K.). Recurrence-free survival (RFS) time was
defined either by loco-regional relapse or the appearance of a
distant metastasis, and whichever shorter if both applicable. The
study was a retrospective analysis. General written consent was
obtained from all patients at time of surgery. The samples were
anonymised for the study. The study was approved by the Ethical
Committee of the Semmelweis University (IKEB #7/2008 and
#7-1/2008).
Patient characteristics
In line with bioinformatics, the clinicopathological properties of
the selected 185 breast cancer patients were analyzed. The mean
age of patients was 58.8612.8 years (59.9611.8 years, 59.2613.0
years, 56.5613.7 years in grade 1, 2 and 3 tumor groups,
respectively). Among the histological types, invasive ductal
carcinoma was the most common overall (65.9%), but less
frequent types of cancer were also included in the analysis
(8.1%): 1 papillary, 1 tubular, 1 micropapillary and 3 mucinous
carcinomas in the grade 1 group; 1 micropapillary and 1
mucionous in grade 2; and 4 with medullary features, 2
metaplastic and 1 micropapillary carcinomas in grade 3 cancers.
Tumor size, frequency of vascular invasion, presence of necrosis,
Nottingham Prognostic Index (NPI) and number of relapses
showed an increase, while ER, PgR expression and RFS decreased
with higher grade (Table 1). When characterizing tumors
according to immunophenotype, expression of ER, PgR and
Her2 were evaluated and fluorescence in situ hybridisation (FISH)
was performed to assess Her2 amplification. ER and PgR
expressing tumors with lower than 20% Ki67 expression were
considered as Luminal A (LumA). For ER or PgR and Her2
positive tumors and ER and PgR expressing tumors with more
than 20% Ki67 index, Luminal B subtype (LumB) was assigned
[22]. Her2 expressing and/or Her2 amplified and ER and PgR
negative tumors were considered as the Her2 subgroup (none were
treated with trastuzumab at that time). Triple negative breast
cancers (TNBC) were ER, PgR, Her2 negative tumors with no
Her2 amplification. The disease free survival of patients in the
different grade- and immunophenotype groups were plotted on
Kaplan-Meier graphs (Figure S1).
RNA purification and qPCR
Five to ten 5 mm thick sections were used from each case for
RNA purification after assessment of cellularity on HE stained
slides (minimum of 70% tumor cell content was required). RNA
was extracted with Qiagen FFPE RNeasy kit according to the
manufacturer’s protocol (Qiagen, Venlo, The Netherlands). High
Capacity RNA-to-cDNA kit was used to reverse transcribe
1000 ng of RNA (Applied Biosystems, Foster City, CA, USA).
The Eppendorf epMotion 5070 robotic system was used to
transfer samples and reagents to 384-well full-skirted white plates
(Eppendorf, Hamburg, Germany). The qPCR was performed in
duplicates with TaqmanH Assays (Table S2) in Gene Expression
Master Mix (all from Applied Biosystems) according to the
manufacturer’s protocol. The reactions were run in Roche
LightCycler 480 real-time PCR system (Roche Diagnostics,
Mannheim, Germany). The CIN4 signature resulting from the
qPCR measurement was assessed based on the average expression
of the four genes (AURKA, FOXM1, TOP2A, TPX2) normalized
to the average expression of the three control genes. In order to
find robust internal reference control genes for clinical evaluation
of CIN4 by qPCR in formalin-fixed tumor tissue, we chose three
known housekeeping genes which bare consistently low variance in
the microarray profiles of all breast cancer datasets as normalizing
genes: B4GALT3, SLC9A3R2 [23] and PUM1 [24].
Flow cytometry
Flow cytometry was performed for the analysis of ploidy.
Briefly, a 50 mm section was cut from all the FFPE blocks. A scroll
of tissue was placed in a microcentrifuge tube and xylene was
added to remove the paraffin wax. The tissue was then serially re-
hydrated through 100%, 95%, 70% and 50% ethanol for
5 minutes respectively at room temperature. The tissue was
washed twice with distilled water. A suspension of nuclei was made
by incubating the tissue in a 0.5% pepsin solution (Sigma-Aldrich,
Dorset, UK) prepared in 0.9% saline at pH 1.5. Incubation was
carried out at 37uC for 30 minutes. The nuclei were washed once
with PBS, stained with propidium-iodine and analyzed using the
Calibur 1 FACS mashine and CellQuest software (Beckman
Coulter, Buckinghamshire, UK). DNA index was assigned as
follows: diploids were ‘1.0’, a tumor with a DNA index greater
than 1.10 was classified as aneuploid [25].
Statistics
The assignment of each patient into two cohorts using the CIN4
expression signature was performed in the R statistical environ-
ment (R, version 2.10.1) using the package Prediction Analysis for
CIN4 Signature Stratifies Outcome in Breast Cancer
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performing a soft thresholding to produce a shrunken centroid,
which allows the weighting and ranking of genes with high
predictive potential, PAM is capable to classify the samples into
two cohorts. After this assignment, Kaplan-Meier curves were
used to plot the efficiency of the prediction on recurrence-free
survival. Chi-squared test was performed to test relation of qPCR
and FACS assigned cohorts and clinicopathological variables
grouped into categorical variables. Continuous variables were
compared with student’s t-test. Regression models and Cox
multivariate regression analysis was performed using SPSS 15.0
(SPSS Inc., Chicago, IL, USA) and R (version 2.10.1, Vienna,
Austria). We used two-sided tests and set a significance level of
0.05 for accepting the test p-values.
Results
CIN4 signature derived from in silico ranking of CIN70
genes also reflects histological grade
In order to select a more limited set of genes that optimally
reflect the CIN70 signature we retrieved expression profiles for the
CIN70 signature genes from 10 publicly available breast cancer
datasets [1].
The CIN70 genes were then ranked by Pearson’s correlation
coefficients to the CIN score (mean CIN70 expression) within
these breast cancer microarray cohorts [supplementary referenc-
es]. In order to derive a clinically applicable qPCR expression
signature for use in FFPE tissue, containing fewer genes with
equivalent information reflecting mean CIN70 expression [1],
Correlation with grade was not used in selecting the PCR
quantified CIN genes, those were selected purely based on their
highest average correlation coefficients to tumor CIN score. These
four genes (AURKA, FOXM1, TOP2A, TPX2) were termed the
CIN4 signature.
For 5 of the 10 breast cancer microarray cohorts histological
grade was also available. The above listed 4 genes were also highly
correlated with histological grade (Pearson correlation coefficient
above 0.7).
Next, we assessed the association individually on data sets
between the mean-expression level of CIN4 and clinical outcome
across the same 10 cohorts containing expression data from 1928
breast cancers. We observed significant discriminative power
(p,0.05, for all) by CIN4 for the stratification of good from poor
clinical outcome in all of the breast cancer cohorts [supplementary
references]. Therefore, the expression of CIN4 appears almost as
efficient at predicting cancer outcome as the extended CIN25 and
CIN70 signatures. We were able to compare the performance in
silico of the CIN4 signature to a number of previously published
predictors of outcome such as CIN25, CIN70 [1], Ki67, Ivshina’s
molecular grade [11], Ma5 [19], GGI [20], DX21 [17] and
NKI70 [16] in 3 datasets (GIS [11], JBI [20], JBI1 [20,27]). CIN4
performed almost as well as CIN25. The univariate model based
on which the meta analysis performed clearly suggested the HR of
CIN4 is slightly better than the other predictors (Figure S2a),
however, we wanted to know if CIN4 classification adds any
predictive power to existing classifiers (predictorX). In another
analysis, testing the additive power from CIN4 to a given predictor
we determined the following model: survival=CIN4+predic-
torX+CIN4:predictorX. If CIN4 adds any predictive power, the
benefit is represented by a significant interaction (CIN4:predic-
torX). However, we did find that even though CIN4 has a higher
HR in the univariate model it does not add significant predictive
power to other signatures (Figure S2b).
Identification of control genes in datasets and their
variability in the tissue samples
B4GALT3, SLC9A3R2 and PUM1 were previously chosen
based on their low variability in gene expression datasets described
previously [23,24]. The three genes showed low variation between
the investigated samples as well (Table S3).
Table 1. Clinicopathological data of the 185 breast cancer patients included in the analysis.
Groups according to grade 1 2 3 All
Patients (n) 63 62 60 185
Age – years/mean, (range)/ 59.9 (35–95) 59.2 (23–87) 56.5 (29–87) 58.8 (23–95)
Histology (n, %) IDC 45 (71.4%) 37 (59.6%) 40 (66.6%) 122 (65.9%)
ILC 4 (6.3%) 3 (4.8%) 1 (1.6%) 8 (4.3%)
Mixed 8 (12.6%) 20 (32.2%) 12 (20.0%) 40 (21.6%)
Other 6 (9.5%) 2 (3.2%) 7 (11.6%) 15 (8.1%)
Tumour size - mm (mean 6 SE) 20.4961.10 26.8161.54 28.5561.92 25.13613.87
Vascular invasion/n (%)/ 34 (55.5%) 46 (74.1%) 49 (81.6%) 129 (69.7%)
Necrosis/n (%)/ 8 (12.6%) 16 (25.8%) 35 (58.3%) 59 (31.8%)
NPI (mean 6 SE) 3.0060.11 4.3960.13 5.5860.15 4.3961.39
Immunophenotype (n, %) Lum A 55 (87.3%) 40 (64.5%) 22 (36.6%) 117 (63.2%)
Lum B 4 (6.3%) 8 (12.9%) 15 (25.0%) 27 (14.5%)
HER2 0 3 (4.8%) 7 (11.6%) 10 (5.4%)
TNBC 4 (6.3%) 11 (17.7%) 16 (26.6%) 31 (16.7%)
Recurrence (n, %) Local relapse 8 (12.6%) 5 (8.1%) 7 (11.6%) 20 (10.8%)
Distant metastasis 8 (12.6%) 21 (33.8%) 21 (35.0%) 50 (27.0%)
RFS – months/mean (range)/ 85.9 (12–122) 75.9 (0–123) 74.1 (0–119) 78.8 (0–123)
doi:10.1371/journal.pone.0056707.t001
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Expression of CIN4 was assessed in a retrospective cohort of
185 patients for which we had FFPE primary breast cancer
samples available from Buda MA ´V hospital, treated between 1999
and 2002 (Table 1). Kaplan-Meier curves of the pathological
evaluation of Ki67 expression and mitotic index performances on
prognosis are shown in Figure S3.
In order to define a threshold for CIN4 expression for distinct
outcome groups, we trained the PAM algorithm using the
continuous CIN4 gene expression signature to discriminate clinical
outcome of 63 patients with grade 1 breast cancer compared to the
poorer outcome associated with 60 grade 3 breast cancers from
within this cohort of 185 patients. Using this CIN4 expression
threshold that best distinguished grade 1 compared to grade 3
breast cancers, the PAM defined CIN4 score was established, and
we assessed the ability of this CIN4 score to stratify cancer
outcome in the remaining 62 patients with grade 2 breast cancer
from this 185 patient cohort.
Using this threshold, the CIN4 score was able to stratify patients
with grade 2 breast cancers into good (44 patients) and poor (18
patients) prognostic groups (mean, relapse-free survival: 83.8 months
[95%CI: 73.6–94.2] and 69.4 months [95%CI: 55.1–90.6],
respectively [p=0.016], HR=2.155[1.007–4.612]) (Figure 1A).
Performance of the components of the CIN4 signature/
score regardless of immunophenotype
For the identified genes that have been previously described to
be of prognostic value, we have evaluated the prognostic power of
AURKA, FOXM1, TOP2A, and TPX2 separately. Although, in
public breast cancer datasets (grade 2, follow-up: 10 years,
n=497, split at median) all the genes showed strong predictive
potential (AURKA: p=0.047, HR=1.33[1.00–1.78]; FOXM1:
p,0.001, HR=1.69[1.26–2.27]; TOP2A: p,0.001,
HR=1.68[1.26–2.25]; TPX2: p,0.001, HR=1.64[1.23–2.18]
for relapse-free survival (Figure S4), the data generated by qPCR
was unable to distinguish prognostic subgroups for AURKA,
FOXM1, and TPX2 at 10, 25, 75, 90 percentiles, median or
average expression in our limited number of patients (Table S4).
While TOP2A was already able to split prognostic subgroups at 25
percentile and median expression by itself (Table S4). The gain in
performance is presented in the same table when considering all
the four (CIN4) genes simultaneously.
Performance of CIN4 in ER positive breast tumors
We assessed the performance of the CIN4 score in ER+/
HER22 tumors classified by immunohistochemistry. This cohort
was also stratified into good and poor prognostic groups with
reasonable confidence (p=0.009, HR=2.269[1.117–5.486],
Figure 1B), suggesting that the CIN4 score-defined group with
poor outcome is not driven by the worse outcome of the HER2+
subgroup diagnosed and treated before the introduction of
trastuzumab. Other subtypes were under-represented and com-
parison could not be made in the herein investigated cohort.
CIN4 expression signature reflects aneuploidy directly
quantified by FACS analysis
We assessed tumor DNA index through flow cytometry,
classifying cancers into aneuploid and diploid categories according
to standard threshold (threshold=1.10 [25]). We evaluated the
relationship of DNA index and the CIN4 expression by regression
analysis. The variables showed a significant relationship between
CIN4 expression and increasing DNA index (p=0.036, Figure 2A).
From Fig. 2A, a substantial proportion of tumors with high CIN4
scores have a normal DNA ploidy (diploid cases: 44 below, 48
above mean expression of CIN4 signature; aneuploid cases: 34
below, 50 above mean expression of CIN4 signanture). In this
cohort, aneuploid tumors defined by flow cytometry were
relatively enriched within the grade 3 tumor group (Figure 2B).
As expected, when all breast tumors were considered, ploidy status
correlated with histological grade (p=0.004).
CIN4 expression signature and DNA index correlates with
clinicopathological variables
Using regression analysis, considering all 185 patients, the CIN4
expression signature was significantly correlated with mitotic index
Figure 1. CIN4 is prognostic in the evaluated patients’ samples.
A) The 4-gene signature based, PAM designated CIN4 score showing
discrimination between grade 2 good and poor prognostic groups
plotted on Kaplan-Meier curve in the validation group (p=0.017): 45
cases (38 ER+,7E R 2) in low CIN4 score group and 17 cases (10 ER+,7
ER2) in high CIN4 score group. B) The CIN4 score performing in ER+
tumors only: 38 cases in low CIN4 score group and 10 cases in high
CIN4 score group (p=0.009).
doi:10.1371/journal.pone.0056707.g001
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suggesting that proliferation is correlated with tumor aneuploidy
(p=0.014, p=0.023, respectively; Figure 3B and D). The
Nottingham Prognostic Index (Figure 3E and F) or tumor size
(Figure 3G and H) showed a trend only towards correlation with
CIN4 signature or with DNA index.
Estrogen and progesterone receptor expression as measured by
IHC inversely correlated with CIN4 expression (p=0.012,
p=0.017, respectively, Figure S5A and S5B). HER2 expression
and HER2/C17 FISH counts correlated with CIN4 expression
(p=0.001, p=0.013, respectively, Figure S5C and S5D), indicat-
ing that ER negativity and HER2 positivity are associated with
higher CIN4 expression. The data derived from a qPCR
assessment of CIN4 mRNA expression from FFPE breast cancers,
confirms that the expression of this signature appears to be
relatively enriched within ER negative and HER2 positive breast
cancers (Figure S6).
CIN4 outperforms known clinical clinicopathological
parameters in multivariate outcome models
CIN4 score and clinicopathological variables were tested for
their correlation in grade 2 cancers (Table S5). Cox multivariate
regression analysis was then performed in grade 2 breast
carcinomas: in multiple models CIN4 outperformed clinicopath-
ological variables including hormone receptor status, tumor size,
Figure 2. CIN4 expression correlates with ploidy. A) Regression curve showing relation of CIN4 expression signature and DNA index (p=0.036).
B) Bar graph showing numbers of diploid and aneuploid cases grouped according to histological grade: grade 3 tumors are relatively enriched in
aneuploid cancers.
doi:10.1371/journal.pone.0056707.g002
Figure 3. CIN4 and ploidy and their relation to pathological variables. Relation of CIN4 and DNA index to A) and B) mitotic index, C) and D)
Ki67 expression, E) and F) Nottingham Prognostic Index and G) and H) tumor size displayed with regression curves (coefficients and p-values on
graphs).
doi:10.1371/journal.pone.0056707.g003
CIN4 Signature Stratifies Outcome in Breast Cancer
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concordance indices the models’ quality is only modest (Table 2).
Discussion
In this study, we developed a 4 gene-based measure of CIN
applicable to FFPE material demonstrating clinical utility as a
fairly robust marker of breast cancer prognosis. Aneuploidy
determined by FACS-based DNA index correlated with the CIN4
signature, indicating that the CIN4 signature may in fact serve as a
surrogate method to determine tumor aneuploidy status.
These data derived from a qPCR assessment of CIN4 mRNA
expression from FFPE breast cancers, seems to confirm our
previous analysis from microarray expression datasets [5], that
CIN signature expression appears to be relatively enriched within
ER negative breast cancers as well.
Directly or indirectly quantifying CIN in human tumor biopsies
may hold significant potential for clinical practice [2,7,10,28,29].
The aim of the current work has been to establish such a gene
expression based indirect measure and validate its utility in an
already existing retrospective FFPE cohort. In multivariate
regression analysis the CIN4 signature confers prognostic power
in comparisons across grade 2 cancers specifically. ER status and
vascular invasion showed predictive power, while the CIN4 score
seems to outperform mitotic index and Ki67 expression in
multivariate analysis.
The CIN4 signature performed comparably to previously
published gene signatures in similar cohorts. For example, the
previously published Genomic Grade Index was further simplified
and converted into a qPCR-based test from formalin-fixed,
paraffin-embedded tissues [13,20]. It examines the expression of
4 genes, CDC2, CDC20, KPNA2 and MYBL2 and its utility has
been demonstrated to predict outcome following tamoxifen
treatment. A 5-gene assay was also developed quantifying the
expression of CHDH, HOXB13, IL17BR, MIB1 and MKI67 to
identify a subgroup of early stage estrogen receptor–positive breast
cancer patients with very poor outcome despite endocrine therapy
[19]. Considering the previously published correlation between
Genomic Grade Index and CIN [1,20], it is reassuring to see that
both CIN4 and the 4-gene Genomic Grade Index signature yield
similar results [13,30], indicating that replacing histological grade
2 with gene expression based low and high risk cases could be
considered in prospective studies.
Interestingly, in the study we identified a group of samples with
a diploid DNA index which have a wide range of CIN scores.
There might be several explanations behind this phenomenon
including tumor heterogeneity or the presence of yet unknown
other compensatory mechanisms [31]. Clearly, a substantial
proportion of tumors with high CIN4 scores have a normal
DNA ploidy, indicating that the CIN4 score likely reflects factors
in addition to DNA copy number. In these cases, it is possible that
highly proliferative cells, although with relatively stable genomes,
may have high levels of the genes comprising the signature
While establishing a qPCR-based simple test to improve
histological classification is an important clinical goal, – following
further validation – the CIN4 signature as a quantifier of CIN is
expected to serve as a potential marker of other clinical
characteristics as well. Most prominently, the putative role of
CIN in determining taxane response would suggest that the
predictive role of CIN4 should be tested in the neoadjuvant setting
when comparing response to therapy with or without taxanes in
the treatment of hormone receptor negative breast cancer.
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